摘要
目的:研究人肺腺癌细胞系SPC-A1 mRNA基因转染的树突状细胞(dendritic cells,DCs)和细胞因子诱导活化杀伤细胞(cytokine induced killer,CIK)体内协同抗瘤活性。方法:按常规方法分离健康人外周血单个核细胞,并分别诱导培养为DC和CIK细胞。将人肺腺癌细胞mRNA转染DC细胞,并将转染后成熟DC与CIK细胞混合培养,流式细胞仪检测混合培养前后的CIK细胞表型变化,并通过建立人肺腺癌细胞移植模型研究其体内的协同抗肿瘤活性。结果:混合培养后的CIK细胞表面CD3+CD8+及CD3+CD56+表达显著升高,P<0.01;共孵育后的mRNA-DC-CIK细胞组与其余各组相比,体内肿瘤抑制效率明显增大。结论:利用该方法来负载DC瘤苗具有可行性,为临床上解决DC瘤苗因肿瘤抗原的来源困难问题及提高CIK细胞的特异性抗肿瘤活性提供实验依据,为肺癌的治疗开辟一种新的有效的免疫治疗策略。
OBJECTIVE: To study the co-antitumor effect of cytokine induced killer(CIK) cells and dendritic cells(DCs) transfected with human adenocarcinoma of lung cell line SPC-A1 mRNA.METHODS:The peripheral blood mononuclear cells were isolated and induced into DC and CIK cells.The health human peripheral blood DC cells were transfected with human adenocarcinoma of lung cell line SPC-A1 mRNA,and then co-cultured with CIKcells,and the surface markers on CIK cells were tested with flow cytometry.The anti-tumor activit...
出处
《中华肿瘤防治杂志》
CAS
2008年第12期890-893,共4页
Chinese Journal of Cancer Prevention and Treatment
基金
福建省自然科学基金(F00019)
